Reducing De Novo Donor-Specific Antibody Levels during Acute Rejection Diminishes Renal Allograft Loss
Top Cited Papers
Open Access
- 1 May 2009
- journal article
- Published by Elsevier BV in American Journal of Transplantation
- Vol. 9 (5), 1063-1071
- https://doi.org/10.1111/j.1600-6143.2009.02577.x
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute RejectionTransplantation, 2008
- Renal allograft biopsies in the era of C4d staining: the need for change in the Banff classification systemTransplant International, 2007
- Peritubular capillary C4d staining in late acute renal allograft rejection - is it relevant?Clinical Transplantation, 2007
- Banff ’05 Meeting Report: Differential Diagnosis of Chronic Allograft Injury and Elimination of Chronic Allograft Nephropathy (’CAN’)American Journal of Transplantation, 2007
- Four-year Follow-up of a Prospective Trial of HLA and MICA Antibodies on Kidney Graft SurvivalAmerican Journal of Transplantation, 2007
- The classification and treatment of antibody-mediated renal allograft injury: Where do we stand?Kidney International, 2007
- Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome1Transplantation, 2003
- Role of Complement in Glomerular InjuryKidney and Blood Pressure Research, 1996
- Capillary deposition of C4d complement fragment and early renal graft lossKidney International, 1993
- Vascular deposition of complement-split products in kidney allografts with cell-mediated rejectionClinical and Experimental Immunology, 1991